Literature DB >> 1381131

Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1).

D Grimm1, F Hofstädter, J Bauer, T Spruss, P Steinbach, G Bernhardt, R Menze.   

Abstract

In the present study the establishment and characterization of a new oxyphilic papillary thyroid carcinoma cell line--ONCO-DG1- is given. With immunohistological, histochemical and flow cytometric methods, ONCO-DG 1 cells revealed features of epithelial differentiation. Furthermore the cells formed von Kossa-positive deposits resembling psammoma bodies in monolayer and spheroid culture until late passages. The tumor cell line is now in the 40th subculture. Because of the ability to form multicellular tumor spheroids (MCTS), this cell line is a good model for examining the interaction between thyroid tumor cells and confluent human endothelial cells on extracellular matrix in vitro. It is also suitable for xenotransplantation studies, because it is tumorigenic in NMRI nude mice in vivo.

Entities:  

Mesh:

Year:  1992        PMID: 1381131     DOI: 10.1007/bf02899670

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  2 in total

1.  Functional analysis of three novel cell lines derived from human papillary thyroid carcinomas with three different clinical courses.

Authors:  Mayumi Ishikawa; Toshiaki Tachibana; Hisashi Hashimoto; Junko Toyomura; Toshihide Ito; Kumiko Tsuboi; Kazutoshi Shibuya; Takahisa Hirose; Shiro Minami; Gen Yoshino
Journal:  Hum Cell       Date:  2014-02-25       Impact factor: 4.174

2.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Authors:  Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2008-08-19       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.